AI News NQ Analysis

Triad Japan Releases Report on Schizophrenia Online Seminar for International Clinical Trials Day

NQ Score 78/100

AI Summary (NQ-processed)

On International Clinical Trials Day, Triad Japan released a report on its successful online seminar for schizophrenia patients and families. The event, part of its PPI activities, deepened understanding of treatments and clinical trials, receiving positive feedback from over 90% of attendees.

AI Analysis

Frequently Asked Questions

Q: What is International Clinical Trials Day?
A: Celebrated on May 20th, it commemorates the world's first clinical trial conducted in 1747. It is a day to recognize the importance of clinical trials and to thank the participants, whose cooperation is essential.
Q: What was the purpose of Triad Japan's online seminar?
A: The seminar aimed to address the daily concerns of individuals with schizophrenia and their families, provide accurate knowledge about treatment options and the latest trends, and explain the basics of new drug development and clinical trials.
Q: Who is Triad Japan?
A: Triad Japan is a Site Management Organization (SMO) founded in 1995 that supports medical institutions in conducting clinical trials, with a particular expertise in psychiatric and neurological fields like schizophrenia and Alzheimer's disease.
Q: What were the results of the seminar according to the post-event survey?
A: The survey showed that over 90% of participants felt their understanding of schizophrenia treatment and clinical trials had deepened. Additionally, over 60% reported that their image of clinical trials had improved after attending.
Q: What is PPI (Patient and Public Involvement)?
A: PPI is an initiative to incorporate the perspectives of patients and the public into medical research and development. Its importance is growing globally, promoting a model of 'healthcare created together with patients'.